- Home
- IMNN vs TLPH Comparison
IMNN vs TLPH Comparison
Compare IMNN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNN | TLPH |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 37.9M |
| IPO Year | 2000 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IMNN | TLPH |
|---|---|---|
| Price | $2.81 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $182.61 | $6.00 |
| AVG Volume (30 Days) | 18.7K | ★ 200.2K |
| Earning Date | 05-11-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $0.38 |
| 52 Week High | $9.32 | $1.57 |
Technical Indicators
Market Signals| Indicator | IMNN | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 41.36 |
| Support Level | $0.48 | $0.76 |
| Resistance Level | $4.26 | $0.79 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 27.11 | 32.65 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.